XML 82 R73.htm IDEA: XBRL DOCUMENT
v3.23.3

PFIZER PROMOTION AGREEMENT (Details) - Cologuard promotion agreement - Pfizer Inc - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended |
--- | --- | --- | ---
Sep. 30, 2022 | Sep. 30, 2022 | Nov. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Contract termination fee |  |  | $ 35.9
Service fee based on incremental gross profits over specified baselines and royalties | $ 2.5 | $ 7.5 |
Charges for promotion, sales and marketing | $ 20.6 | $ 86.1 |

X
- Definition Contract Termination Fee + References No definition available. + Details
Name: | exas_ContractTerminationFee
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents service fee based on incremental gross profits over specified baselines and royalties. + References No definition available. + Details
Name: | exas_ServiceFeeBasedOnIncrementalGrossProfitsOverSpecifiedBaselinesAndRoyalties
Namespace Prefix: | exas_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_MarketingExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_ManufacturedProductOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=exas_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |